RE:RE:New on thatIMO TST had one drug (with questionable results) that was rejected by the FDA. That is the risk you take in small bio-tech investing. I did DD on TST a while back and decided not to invest. IMO MCNA is dead and it was a dream to think any more value than 0.14 per share was to be found from it.
I have done DD on PLI and am heavily invested. This is a great opportunity for TST share holders to regain value in their investment. PLI has many possible drugs, not all need to work for success of the company. TST's Belleville plant will likely be used to double PLI capacity to extract proteins from blood plasma. To date they have annouced 5 different proteins and at least one of these, Plasminogen will likely be blockbuster. It is entering clincal trials for chronic wounds, something PLI and its partners have already shown works in humans. Then there is the small molcule side of the company with huge potential in fibrosis/diabetes and other indications. Just one of these indications is worth multiples of PLI value. The current challenge with PLI is how it funds itself. TST $34+ M will go a long way to getting PLI to this time next year when its first protein will start bringing in significant (maybe $100+M) in revenue.
To TST share holders, if you haven't done DD in PLI, spend some time on it.
A good move may be to sell TST at 0.14 and buy PLI now, as PLI has a good chance of being of higher value by November.